Amanote Research
Register
Sign In
Monitoring Renal Safety in Mineralocorticoid Receptor Antagonist Trials
European Journal of Heart Failure
- United States
doi 10.1002/ejhf.764
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cardiovascular Medicine
Cardiology
Date
April 1, 2017
Authors
Faiez Zannad
Publisher
Wiley
Related search
Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure
JAMA - Journal of the American Medical Association
Medicine
Renal Mineralocorticoid Receptor Expression Is Reduced in Lipoatrophy
FEBS Open Bio
Biochemistry
Genetics
Molecular Biology
Differential Impacts of Mineralocorticoid Receptor Antagonist Potassium Canrenoate on Liver and Renal Changes in High Fat Diet-Mediated Early Hepatocarcinogenesis Model Rats
Journal of Toxicological Sciences
Medicine
Toxicology
Effects of Mineralocorticoid Receptor Antagonist Spironolactone on Atrial Conduction and Remodeling in Patients With Heart Failure
Journal of Cardiology
Cardiovascular Medicine
Cardiology
Tailoring Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Patients: Are We Moving Towards a Personalized Approach?
European Journal of Heart Failure
Cardiovascular Medicine
Cardiology
Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
Frontiers in Pharmacology
Pharmacology
Mineralocorticoid Antagonist Improves Glucocorticoid Receptor Signaling and Dexamethasone Analgesia in an Animal Model of Low Back Pain
Frontiers in Cellular Neuroscience
Molecular Neuroscience
Cellular
Third-Generation Mineralocorticoid Receptor Antagonists
Journal of Cardiovascular Pharmacology
Cardiovascular Medicine
Pharmacology
Cardiology
Biased Safety Reporting in Blinded Randomized Clinical Trials: Meta-Analysis of Angiotensin Receptor Blocker Trials
PLoS ONE
Multidisciplinary
